Investing.comCodex · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 02:44:35·⟳ 抓取 02:45:28 +53s·⚡ 决策 08-29 02:47:06 +1m38s·59.7 天前
10x Genomics旗下Scale专利案胜诉，陪审团认定Parse故意侵权并判赔480万美元
事件真实且方向清楚，但已判赔金额对TXG.US和QGEN.US都过小；更有弹性的禁令与增强赔偿仍是后续请求而非已裁定事实，且缺少可执行实时行情，因此不下单。
📄 原文Investing.com↗ 原文
Jury finds Parse Biosciences willfully infringed Scale patents
Wall Street slightly lower amid hawkish Warsh at Jackson Hole, Mag 7 gains PLEASANTON, Calif. - A jury in the U.S. Dist…
不做 10x Genomics（TXG.US）
胜诉利多但480万美元判赔相对收入和市值太小，禁令及增强赔偿仍未裁定，且未取得可执行实时价。
不做 Qiagen（QGEN.US）
旗下Parse败诉偏负面，但涉案产品销售和赔偿金额对集团量级有限，不满足强空催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这是一条专利诉讼胜诉/败诉事件：10x Genomics通过Scale专利获得480万美元陪审团判赔，并可能继续申请增强赔偿和禁令；但480万美元仅约为10x 2026年收入指引的0.8%、约为其近期84亿美元市值的0.06%，对Qiagen侧也只是子公司Parse一条产品线的历史销售特许权费问题，短线基本面弹性不足以覆盖诉讼后续不确定性和执行价缺口。
消息传播链
- 报道称特拉华陪审团当天认定Parse故意侵犯Scale三项专利并判赔超过480万美元，未能打开原文页核验发布时间以外的更多元数据。
关键理由
- 10x Genomics胜诉确认了Scale三项细胞测序相关专利的有效性和可执行性，方向上有利于其知识产权护城河。
- 按480万美元判赔和14%费率反推，涉案Parse历史销售额约3430万美元，年化规模有限。
- 10x 2026年收入指引为61000万至63000万美元，本次已判赔金额仅约占全年收入0.8%、占近期市值约0.06%，短线业绩增量不够强。
主要风险
- 真正可能放大影响的是永久禁令、增强赔偿和律师费，但这些仍处于post-trial申请阶段，尚非确定现金流。
- 10x Genomics股价8月已从约45美元上行至64美元附近，近期主要由财报和产品预期重定价，本次小额判赔的新增edge有限。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-20 · 影响 weakens
Parse此前刚宣布在另一组10x专利IPR上诉中获胜，削弱把本次裁决解读为10x专利战全面胜利的强度。
检索:Parse Biosciences wins patent dispute with 10x Genomics August 2026 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-28 · 影响 weakens
按480万美元判赔和14%费率反推涉案历史销售额约3430万美元，年化约600万美元，尚不足以构成Qiagen强空催化。
检索:Qiagen Parse Biosciences patent verdict damages 14% royalty Evercode sales materiality 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足加上本次金额很小，使交易从方向性利好/利空降为不做。
方向:可比样本不足；低相似样本提示专利诉讼对股价的关键不是胜负本身，而是赔偿、持续royalty和产品覆盖比例。
涨幅量级:没有足够高相似、同市场、同量级且首发锚干净的样本可校准TXG或QGEN涨跌幅。
形态:未形成可用的见光死或持续重估模式。
历史先例(按相似度)
- 相似度 5/10 GH.US 2026-08-25 Guardant因专利败诉、24520万美元以上赔偿及核心产品未来6% royalty而下跌。 原文 ↗
事件后 +1日 +1.1% · +2日 +4.7% · +3日 +3.3%
⚠来源层级不符(声明media/实为issuer) — 该行涨幅别用来定止盈止损
相似度依据:同为生命科学/诊断相关专利败诉，但Guardant判赔及持续royalty覆盖核心产品约90%收入，量级远高于本次。
经验:专利败诉只有在赔偿和未来royalty触及核心收入时才容易形成强股价冲击。
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 1,951 字
Wall Street slightly lower amid hawkish Warsh at Jackson Hole, Mag 7 gains
PLEASANTON, Calif. - A jury in the U.S. District Court for the District of Delaware ruled today that Parse Biosciences, now a subsidiary of Qiagen (NYSE:QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics (NASDAQ:TXG) since 2025, according to a press release statement.
The patents are exclusively licensed from Roche Sequencing Solutions. The jury rejected Parse’s challenges to the validity of the patents, finding all three patents valid and enforceable.
The jury awarded 10x Genomics over $4.8 million in damages for sales of Parse’s Evercode Whole Transcriptome products from February 2021 through June 30, 2026. The damages award is based on a 14% royalty rate on infringing Parse sales.
10x Genomics plans to seek additional awards in post-trial proceedings, including enhanced damages and attorneys’ fees for Parse’s willful infringement, and a permanent injunction to stop further infringement by Parse in the United States.
The patents adjudicated at trial are U.S. Patent Nos. 10,626,442, 10,982,256, and 11,512,341.
"Today’s verdict is a win for inventors," said Garry Nolan, co-founder of Scale Biosciences. "It affirms that original ideas matter and that strong patent rights are essential to advancing science."
Randy Wu, General Counsel of 10x Genomics, said the evidence presented at trial showed that Parse made a deliberate decision to ignore the patents. "We are pleased with today’s verdict, which makes clear that companies cannot simply benefit from the innovation of others and disregard the patent rights protecting them," Wu stated.
10x Genomics acquired Scale Biosciences in 2025. The company develops instruments, consumables and software for single cell and spatial biology research.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PLEASANTON, Calif. - A jury in the U.S. District Court for the District of Delaware ruled today that Parse Biosciences, now a subsidiary of Qiagen (NYSE:QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics (NASDAQ:TXG) since 2025, according to a press release statement.
The patents are exclusively licensed from Roche Sequencing Solutions. The jury rejected Parse’s challenges to the validity of the patents, finding all three patents valid and enforceable.
The jury awarded 10x Genomics over $4.8 million in damages for sales of Parse’s Evercode Whole Transcriptome products from February 2021 through June 30, 2026. The damages award is based on a 14% royalty rate on infringing Parse sales.
10x Genomics plans to seek additional awards in post-trial proceedings, including enhanced damages and attorneys’ fees for Parse’s willful infringement, and a permanent injunction to stop further infringement by Parse in the United States.
The patents adjudicated at trial are U.S. Patent Nos. 10,626,442, 10,982,256, and 11,512,341.
"Today’s verdict is a win for inventors," said Garry Nolan, co-founder of Scale Biosciences. "It affirms that original ideas matter and that strong patent rights are essential to advancing science."
Randy Wu, General Counsel of 10x Genomics, said the evidence presented at trial showed that Parse made a deliberate decision to ignore the patents. "We are pleased with today’s verdict, which makes clear that companies cannot simply benefit from the innovation of others and disregard the patent rights protecting them," Wu stated.
10x Genomics acquired Scale Biosciences in 2025. The company develops instruments, consumables and software for single cell and spatial biology research.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。